Whitepapers/App Notes/Posters

Whitepaper: Considerations in support of achieving successful double blinding and removing bias with over encapsulation

Posted: 11 September 2020 | | No comments yet

This whitepaper explores critical factors for over-encapsulation success. DBcaps® capsules offer a convenient option for blinding in clinical trials.

Over-encapsulation is a powerful tool which will be widely used throughout clinical trials for years to come. Patient-centric efforts of manufacturers and trial sponsors have forged a path for innovative products such as DBcaps®, to ensure the integrity of their study and avoid bias. Consideration must be given to the capsule’s compatibility with encapsulated products – dissolution, diffusion and stability studies are essential elements of selection. HPMC capsules offer a range of development benefits that complement traditional hard-gelatin capsules. This increases accessibility for sponsors and gives them greater flexibility and product compatibility when selecting their dosage format. We understand and control every step of over-encapsulation—from material selection to manufacture—and will leverage a simple, efficient means to flexibility and success in your double blinded clinical trials.











To read this whitepaper in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Lonza

Send this to a friend